Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 35584336

Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
J Clin Oncol
Publication date
2022 Oct 1
First author
Bidard FC

This record carries publication-notice metadata. Review the notices below before relying on it.

Publication notices

absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    J Clin Oncol. 2022 Oct 1;40(28):3227-3229. doi: 10.1200/JCO.22.00841.
    note
    Source null
    related pmid
    35737918
    relationship
    Comment in
  2. citation
    J Clin Oncol. 2022 Dec 20;40(36):4280-4281. doi: 10.1200/JCO.22.01454.
    note
    Source null
    related pmid
    36067450
    relationship
    Comment in
  3. citation
    J Clin Oncol. 2023 Aug 10;41(23):3962. doi: 10.1200/JCO.23.01239.
    note
    Source null
    related pmid
    37364222
    relationship
    Erratum in

Authors and identifiers

  1. name
    Bidard FC
    type
    Author
  2. name
    Kaklamani VG
    type
    Author
  3. name
    Neven P
    type
    Author
  4. name
    Streich G
    type
    Author
  5. name
    Montero AJ
    type
    Author
  6. name
    Forget F
    type
    Author
  7. name
    Mouret-Reynier MA
    type
    Author
  8. name
    Sohn JH
    type
    Author
  9. name
    Taylor D
    type
    Author
  10. name
    Harnden KK
    type
    Author
  11. name
    Khong H
    type
    Author
  12. name
    Kocsis J
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Bidard FC
    type
    Author
  2. name
    Kaklamani VG
    type
    Author
  3. name
    Neven P
    type
    Author
  4. name
    Streich G
    type
    Author
  5. name
    Montero AJ
    type
    Author
  6. name
    Forget F
    type
    Author
  7. name
    Mouret-Reynier MA
    type
    Author
  8. name
    Sohn JH
    type
    Author
  9. name
    Taylor D
    type
    Author
  10. name
    Harnden KK
    type
    Author
  11. name
    Khong H
    type
    Author
  12. name
    Kocsis J
    type
    Author
bibliography ids
  1. nci-bib-cd404773fe22186bd1274437
book metadata
content sha256
cc60dd3fe6c6ecd551fa39c80c7d11a09ec569918325984ef3e75bd724b18f5f
document type
citation
dois
  1. 10.1200/JCO.22.00338
electronic publication date
display
2022 May 18
precision
day
year
2022
evidence scope
bibliographic_metadata_only
id
pubmed:35584336
immutable id
pubmed:35584336@cc60dd3fe6c6ecd551fa39c80c7d11a09ec569918325984ef3e75bd724b18f5f
journal
abbreviation
J Clin Oncol
issn electronic
1527-7755
issn print
0732-183X
issue
28
name
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
nlm unique id
8309333
pages
3246-3256
volume
40
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    J Clin Oncol. 2022 Oct 1;40(28):3227-3229. doi: 10.1200/JCO.22.00841.
    note
    Source null
    related pmid
    35737918
    relationship
    Comment in
  2. citation
    J Clin Oncol. 2022 Dec 20;40(36):4280-4281. doi: 10.1200/JCO.22.01454.
    note
    Source null
    related pmid
    36067450
    relationship
    Comment in
  3. citation
    J Clin Oncol. 2023 Aug 10;41(23):3962. doi: 10.1200/JCO.23.01239.
    note
    Source null
    related pmid
    37364222
    relationship
    Erratum in
outcomes validated
false
pmid
35584336
provenance
batch id
9d150d55960e0c12aada
provider
NCBI PubMed ESummary
record sha256
19882967b9aaaf24a04eaf9d8317358b69ac8285ca3c647f5435865fe9dd6c70
response sha256
2d4ef1cc8137eef6e7216f66bf8601c3899bc663b8626f412794d39585de6b6b
retrieved at
2026-09-09T23:48:09.820498+00:00
publication date
display
2022 Oct 1
precision
day
year
2022
publication types
  1. Clinical Trial, Phase III
  2. Journal Article
  3. Randomized Controlled Trial
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/35584336/
title
Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial.

Preserved source evidence · Not medical advice